Hypoxia and Hormone-Mediated Pathways Converge at the Histone Demethylase KDM4B in Cancer

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2018 Jan 19

PMID 29342868

Citations 16

Authors

Jun Yang

Adrian L Harris

Andrew M Davidoff

Affiliations

Soon will be listed here.

Abstract

Hormones play an important role in pathophysiology. The hormone receptors, such as estrogen receptor alpha and androgen receptor in breast cancer and prostate cancer, are critical to cancer cell proliferation and tumor growth. In this review we focused on the cross-talk between hormone and hypoxia pathways, particularly in breast cancer. We delineated a novel signaling pathway from estrogen receptor to hypoxia-inducible factor 1, and discussed the role of this pathway in endocrine therapy resistance. Further, we discussed the estrogen and hypoxia pathways converging at histone demethylase KDM4B, an important epigenetic modifier in cancer.

Citing Articles

Understanding human aging and the fundamental cell signaling link in age-related diseases: the middle-aging hypovascularity hypoxia hypothesis.

Phua T Front Aging. 2023; 4:1196648.

PMID: 37384143 PMC: 10293850. DOI: 10.3389/fragi.2023.1196648.

KDM4B down-regulation facilitated breast cancer cell stemness via PHGDH upregulation in H3K36me3-dependent manner.

Wang X, Li H, Xia R, Li X, Zhang X, Jin T Mol Cell Biochem. 2023; 479(4):915-928.

PMID: 37249813 DOI: 10.1007/s11010-023-04777-1.

Prognostic Value of Intracellular Transcription of Factors HIF-1α and p53 and Their Relation to Estradiol and TNM Parameters of Breast Cancer Tissues in Women with Invasive Ductal Carcinoma in Thi-Qar Province, Iraq.

Ali Khadem Z, Abdul Wadood Al-Shammaree S Arch Razi Inst. 2023; 77(4):1341-1348.

PMID: 36883155 PMC: 9985786. DOI: 10.22092/ARI.2022.357640.2080.

Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.

Liu J, Fang W, Yang S, Wu M, Chen T, Chen C J Biomed Sci. 2022; 29(1):29.

PMID: 35534851 PMC: 9082844. DOI: 10.1186/s12929-022-00812-3.

Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response.

Ashrafizadeh M, Paskeh M, Mirzaei S, Gholami M, Zarrabi A, Hashemi F J Exp Clin Cancer Res. 2022; 41(1):105.

PMID: 35317831 PMC: 8939209. DOI: 10.1186/s13046-022-02293-6.

References

Yang J, Jubb A, Pike L, Buffa F, Turley H, Baban D . The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth. Cancer Res. 2010; 70(16):6456-66. PMC: 4261152. DOI: 10.1158/0008-5472.CAN-10-0413. View

Chen J, Liu H, Liu J, Qi J, Wei B, Yang J . H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs. Nat Genet. 2012; 45(1):34-42. DOI: 10.1038/ng.2491. View

Harvey J, Clark G, Osborne C, Allred D . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-81. DOI: 10.1200/JCO.1999.17.5.1474. View

Maxwell P, Wiesener M, Chang G, Clifford S, Vaux E, Cockman M . The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399(6733):271-5. DOI: 10.1038/20459. View

Brunnberg S, Pettersson K, Rydin E, Matthews J, Hanberg A, Pongratz I . The basic helix-loop-helix-PAS protein ARNT functions as a potent coactivator of estrogen receptor-dependent transcription. Proc Natl Acad Sci U S A. 2003; 100(11):6517-22. PMC: 164478. DOI: 10.1073/pnas.1136688100. View

Qiu M, Fan Q, Zhu Z, Kwan S, Chen L, Chen J . KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1. Oncotarget. 2015; 6(31):31702-20. PMC: 4741634. DOI: 10.18632/oncotarget.5165. View

Jaakkola P, Mole D, Tian Y, Wilson M, Gielbert J, Gaskell S . Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001; 292(5516):468-72. DOI: 10.1126/science.1059796. View

Yang J, Milasta S, Hu D, AlTahan A, Interiano R, Zhou J . Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox. Cancer Res. 2017; 77(17):4626-4638. PMC: 5581701. DOI: 10.1158/0008-5472.CAN-16-0826. View

Yang J, Ledaki I, Turley H, Gatter K, Martinez Montero J, Li J . Role of hypoxia-inducible factors in epigenetic regulation via histone demethylases. Ann N Y Acad Sci. 2009; 1177:185-97. DOI: 10.1111/j.1749-6632.2009.05027.x. View

10.

Gerald D, Berra E, Frapart Y, Chan D, Giaccia A, Mansuy D . JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell. 2004; 118(6):781-94. DOI: 10.1016/j.cell.2004.08.025. View

11.

Kandoth C, McLellan M, Vandin F, Ye K, Niu B, Lu C . Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502(7471):333-339. PMC: 3927368. DOI: 10.1038/nature12634. View

12.

Jaiyesimi I, Buzdar A, Decker D, Hortobagyi G . Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol. 1995; 13(2):513-29. DOI: 10.1200/JCO.1995.13.2.513. View

13.

Mueller M, Vigne J, Minchenko A, Lebovic D, Leitman D, Taylor R . Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta. Proc Natl Acad Sci U S A. 2000; 97(20):10972-7. PMC: 27133. DOI: 10.1073/pnas.200377097. View

14.

Kooistra S, Helin K . Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol. 2012; 13(5):297-311. DOI: 10.1038/nrm3327. View

15.

Walters Z, Villarejo-Balcells B, Olmos D, Buist T, Missiaglia E, Allen R . JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene. 2013; 33(9):1148-57. PMC: 3982124. DOI: 10.1038/onc.2013.46. View

16.

Portela A, Esteller M . Epigenetic modifications and human disease. Nat Biotechnol. 2010; 28(10):1057-68. DOI: 10.1038/nbt.1685. View

17.

Castellini L, Moon E, Razorenova O, Krieg A, von Eyben R, Giaccia A . KDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage. Nucleic Acids Res. 2017; 45(7):3674-3692. PMC: 5397198. DOI: 10.1093/nar/gkw1281. View

18.

Brown J, Wilson W . Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004; 4(6):437-47. DOI: 10.1038/nrc1367. View

19.

Groner A, Brown M . Role of steroid receptor and coregulator mutations in hormone-dependent cancers. J Clin Invest. 2017; 127(4):1126-1135. PMC: 5373886. DOI: 10.1172/JCI88885. View

20.

Chi P, Allis C, Wang G . Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 2010; 10(7):457-69. PMC: 3262678. DOI: 10.1038/nrc2876. View